Document Detail

Novel therapeutics for gastro-esophageal reflux symptoms.
MedLine Citation:
PMID:  23121276     Owner:  NLM     Status:  In-Data-Review    
Approximately 20-30% of patients with gastro-esophageal reflux symptoms report inadequate symptom relief while on proton-pump inhibitor therapy. The mechanisms involved are failure of the antireflux barrier (transient lower esophageal sphincter relaxations), high proximal extent of the refluxate, esophageal hypersensitivity and impaired mucosal integrity. Persisting acid or nonacid reflux can be demonstrated in 40-50% of cases, suggesting that there is room for antireflux therapy in these patients. New antireflux compounds have been shown to decrease the occurrence of transient lower esophageal sphincter relaxations. The most promising classes of compounds are GABA type B agonists and metabotropic glutamate receptor 5 antagonists, which can reduce both reflux episodes and symptoms, but the development of these compounds has been abandoned for either safety issues or lack of efficacy. Esophageal hypersensitivity and impaired mucosal integrity may prove to be relevant therapeutic targets in the future.
Frank Zerbib; Mireille Simon
Related Documents :
22460296 - Cerebrospinal fluid β-amyloid(1-42) correlates with rate of progression in alzheimer's...
21986096 - Fluid-attenuated inversion recovery hyperintensity in acute ischemic stroke may not pre...
9174456 - Tendon pathology in long-standing achillodynia. biopsy findings in 40 patients.
3988136 - A novel approach to the analysis of risk factors in endometrial carcinoma.
14720176 - Relationships between arteriosclerosis, cerebral amyloid angiopathy and myelin loss fro...
22192286 - Suppression of erythropoiesis in patients with chronic heart failure and anaemia of unk...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Expert review of clinical pharmacology     Volume:  5     ISSN:  1751-2441     ISO Abbreviation:  Expert Rev Clin Pharmacol     Publication Date:  2012 Sep 
Date Detail:
Created Date:  2012-11-05     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101278296     Medline TA:  Expert Rev Clin Pharmacol     Country:  England    
Other Details:
Languages:  eng     Pagination:  533-41     Citation Subset:  IM    
CHU Bordeaux, Saint André Hospital, Gastroenterology Department, Bordeaux, F-33075, France.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Evidence-based guidelines for pediatric clinical trials: focus on StaR Child Health.
Next Document:  New biologic-response modifiers in ocular inflammatory disease: beyond anti-TNF treatment.